Entries by BioSpace

, , ,

BrainStorm preps for Type A NurOwn meeting, shakes up C-suite

BrainStorm Cell Therapeutics concluded 2022 on a cautiously optimistic note as the FDA granted a Type A meeting to discuss the refuse to file letter it served the Israel and New York-based biotech in November for its ALS hopeful, NurOwn. On Wednesday, the company made a series of C-suite moves in what could be a show of confidence in NurOwn’s ability to prevail.


Chemomab claims mid-stage win in NASH

Topline data from a Phase IIa study showed ChemomAb’s (Chemomab) investigational monoclonal antibody, CM-101, met its primary endpoints of safety and tolerability in nonalcoholic steatohepatitis (NASH), the Israel-based biotech reported Tuesday.